ADVFN Logo
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
TG Therapeutics Inc

TG Therapeutics Inc (TGTX)

25.675
0.425
( 1.68% )
Updated: 11:47:08

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
25.675
Bid
25.66
Ask
25.69
Volume
1,370,003
25.085 Day's Range 26.09
6.46 52 Week Range 26.41
Market Cap
Previous Close
25.25
Open
25.60
Last Trade
5
@
25.7257
Last Trade Time
11:47:13
Financial Volume
$ 35,071,780
VWAP
25.5998
Average Volume (3m)
3,189,877
Shares Outstanding
154,823,137
Dividend Yield
-
PE Ratio
312.47
Earnings Per Share (EPS)
0.08
Revenue
233.66M
Net Profit
12.67M

About TG Therapeutics Inc

TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, ... TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
-
TG Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker TGTX. The last closing price for TG Therapeutics was $25.25. Over the last year, TG Therapeutics shares have traded in a share price range of $ 6.46 to $ 26.41.

TG Therapeutics currently has 154,823,137 shares outstanding. The market capitalization of TG Therapeutics is $3.91 billion. TG Therapeutics has a price to earnings ratio (PE ratio) of 312.47.

TG Therapeutics (TGTX) Options Flow Summary

Overall Flow

Bullish

Net Premium

994k

Calls / Puts

2,200.00%

Buys / Sells

72.73%

OTM / ITM

15.00%

Sweeps Ratio

4.35%

TGTX Latest News

New BRIUMVI® (ublituximab-xiiy) Data from the ENHANCE Phase 3b Study Show Rapid 30-Minute Infusions are Well Tolerated in Patients with Relapsing Forms of Multiple Sclerosis

Infusion related reactions in patients receiving 30-minute BRIUMVI infusions were all mild (Grade 1) and resolved completely Data also demonstrate patients switching from prior anti-CD20...

New Data for BRIUMVI® (ublituximab-xiiy) Demonstrate that 92% of Patients with Relapsing Multiple Sclerosis Were Free from Disability Progression After 5 Years of Treatment

During year 5 of treatment with BRIUMVI the annualized relapse rate was 0.020, equivalent to one relapse occurring every 50 years of patient treatment Overall safety profile of BRIUMVI remained...

Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600 PR Newswire NEW YORK, Sept. 6, 2024 NEW YORK...

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI at the 2024 European Committee for Treatment and Research in Multiple Sclerosis Annual Meeting

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the schedule of upcoming data presentations, highlighting data from both the ULTIMATE I &...

TG Therapeutics Reports Second Quarter 2024 Financial Results and Raises BRIUMVI® (ublituximab-xiiy) Full Year Revenue Guidance

Second quarter 2024 U.S. BRIUMVI net revenue of $72.6 million Raising full year 2024 U.S. BRIUMVI net revenue target to approximately $290 - $300 million Cash flow positive for second quarter...

TG Therapeutics to Host Conference Call on Second Quarter 2024 Financial Results and Business Update

NEW YORK, Aug. 05, 2024 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Tuesday August 6, 2024 at 8:30 AM ET to discuss results for...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
12.82512.36323851222.8526.4122.83375824824.59646141CS
40.5852.3316062176225.0926.4121.11314742523.64130262CS
127.90544.485087225717.7726.4116.8901318987721.78977222CS
2610.62570.598006644515.0526.4112.93309182318.63779824CS
5216.185170.5479452059.4926.416.46420217815.32881733CS
156-4.405-14.644281914930.0835.943.48370906014.27554476CS
26019.245299.3001555216.4356.743.48293049616.91109954CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
GSIWGarden Stage Ltd
$ 6.1099
(169.16%)
24.56M
ZEOZeo Energy Corporation
$ 2.998
(162.98%)
50.47M
TBIOTelesis Bio Inc
$ 2.765
(103.31%)
47.53M
XCURExicure Inc
$ 3.96
(72.93%)
14.32M
EWTXEdgewise Therapeutics Inc
$ 29.485
(54.61%)
7.45M
HAOHaoxi Health Technology Ltd
$ 0.74
(-75.33%)
6.09M
GDHGGolden Heaven Group Holdings Ltd
$ 2.6371
(-36.76%)
341.59k
HOVRNew Horizon Aircraft Ltd
$ 0.51
(-31.17%)
1.29M
PGNYProgyny Inc
$ 17.18
(-29.71%)
10.33M
BLMZBloomZ Inc
$ 0.9827
(-28.27%)
338.52k
NVDANVIDIA Corporation
$ 119.2894
(5.22%)
138.8M
SQQQProShares UltraPro Short QQQ
$ 7.7045
(-8.28%)
122.18M
FRGTFreight Technologies Inc
$ 0.1305
(5.33%)
70.94M
MAXNMaxeon Solar Technologies Ltd
$ 0.1051
(15.62%)
65.97M
TSLATesla Inc
$ 243.005
(6.96%)
52.08M

TGTX Discussion

View Posts
Laster Laster 4 hours ago
I think we will see a delayed (few days) response to the news.
I am expecting that this will run to $27 by next week and $30 by October.
Definite buyout candidate within the next year. Especially if interest rates are dropping.
JMO.
👍️0
murocman murocman 15 hours ago
Could not agree more.

I don’t think they are long for this corporate world as an independent entity.

Murocman
👍️0
Laster Laster 1 day ago
I had to buy some Premarket. This company is a gold mine IMO.
I love stocks near 52 week high. The upward potential here is limitless.
Really excited for the next few months.
I definitely see this company being bought out in the next 52 weeks.
👍️0
Laster Laster 1 day ago
Great news today. Stock at 52-week high.
Just announced $100 million stock buyback.
Compelling story here.
JMO.
👍️0
Monksdream Monksdream 8 months ago
TGTX new 52 week high
👍️0
InspectorBullit InspectorBullit 9 months ago
this should have a very good day tomorrow absent a market meltdown. MS drug par excellence.
👍️0
murocman murocman 11 months ago
I would think we’d be close to the bottom here? Almost at a 52 week low!

GLTA,

Murocman
👍️ 1
kld2 kld2 1 year ago
Cheap at these levels. Should see $20 again before long. Friday should be interesting. If script numbers are good, like last Friday, the share price should get a good boost. Half way through Q3. Dumb drop from $21 to $9.
👍️ 1
Max77 Max77 1 year ago
$TGTX CEO Weiss buys 100k shares at 10.13. Now has 12 million shares
👍️ 1
murocman murocman 1 year ago
Barely above pre-approval prices. Unbelievable.

Murocman
👍️ 1
teifhals teifhals 1 year ago
Anyone catch that Genetech is starting to air commercials since they are losing share?
👍️0
Rayn_Makr Rayn_Makr 1 year ago
Great call this morning. Nice run today and just the beginning with Europe coming on soon.
After Hours Time (ET) After Hours Price After Hours Share Volume
17:27:17 $30.5 5,000
$152,500 in one trade. Short covering???
Fun to think about market cap in 2024 and 2025.
👍️0
Alan Brown Alan Brown 1 year ago
Where did you find such news?
👍️0
Aquahoya Aquahoya 2 years ago
Has anyone checked out $GSTC? Similar biotech company like $TGTX except its much newer and has a patented formulation combinational therapy already FDA approved set and waiting for clinical trial approval in India for Multiple Sclerosis. It is an over-the-counter stock sitting over .01 just waiting for clinical trials approval. The market cap is on $8,000,000. The therapy isn't specific to the type of multiple sclerosis. So, the potential here is huge. The conservative market share that was done by seasoned professionals in the space, that is on their presentation is in the BILLIONs. Read the history here: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=170524593












👍️0
teifhals teifhals 2 years ago
Whens the buyout..?
👍️ 1
Penny chatter Penny chatter 2 years ago
Lol
👍️0
hawkshaw812 hawkshaw812 2 years ago
Looks like tuseday is shorting day .
👍️0
tw0122 tw0122 2 years ago
They have cash and a better MS drug have the price of Roches. Shorts don’t like
👍️0
makinezmoney makinezmoney 2 years ago
$TGTX: Not only that but they must be...............

On the wrong side of the trade.

When you get squeezed on them nards, it never feels good.


No mercy....... TAKE THEM OUT !!!!!!!


GO $TGTX
👍️0
tw0122 tw0122 2 years ago
Analysts keep on giving it bad sell ratings.
That must be a good sign. Analysts for the most part just share selling scam artists
👍️0
makinezmoney makinezmoney 2 years ago
$TGTX: Slowllyy creeping up..... now 11.50 in PreMarket

If it can do exactly what $KALA just did by going over $45, I'm a happy camper


GOOOOOOOOOOOooooooooooooooooooooooooooo hardddddddddddddddddddd



GO $TGTX
👍️0
Ringrock Ringrock 2 years ago
Traded@55.70 Jan 8 ‘21… looks like she’s still got quite a bit togo…
👍️0
shamalamadingdong shamalamadingdong 2 years ago
Dosing of first patients in 30 to 45 days from now/going to the market!!
👍️0
TheFinalCD TheFinalCD 2 years ago
$TGTX No offerings on the horizon per CC

$TGTX No offerings on the horizon per CC lfg— Cooway Trades 🐊 ⛪️🚀🇺🇸🙏🏽 (@cooway) December 29, 2022
👍️0
shamalamadingdong shamalamadingdong 2 years ago
Link to 8;30 webcast/conference call.
https://ir.tgtherapeutics.com/events
👍️0
shamalamadingdong shamalamadingdong 2 years ago
Some informative information, pictures of the packaging, disease overview, and more.
https://ml.globenewswire.com/1.0/snippet/1898/eng
👍️0
shamalamadingdong shamalamadingdong 2 years ago
TG Therapeutics Announces FDA Approval Of BRIUMVI; Company To Host Conference Call On Thursday, December 29, 2022 At 8:30 Am ET
👍️0
airman1 airman1 2 years ago
Given a try; on this one in at 8:47 for a morning was jump !!
See if shorts cover before the weekend ??
👍️0
airman1 airman1 2 years ago
Yeah, we may get mm naked! shorts covering tomorrow. Share price may
spike./;)) early GL$$
👍️0
tw0122 tw0122 2 years ago
They have cash and they would let the price go much higher before another offering
👍️0
tw0122 tw0122 2 years ago
$8.73 after hours On a good note company conference 830am and market makers
👍️0
pennyfinder pennyfinder 2 years ago
Probably an offering coming.
👍️0
tw0122 tw0122 2 years ago
Unfortunately lots of illegal naked shorts courtesy of Gary G but see what happens next few days as more shorts cover.
Never a easy game kept a few shares
👍️0
Cheap Stock Investor Cheap Stock Investor 2 years ago
Damn how low is this going? Not headed in right direction at the moment.
👍️0
tw0122 tw0122 2 years ago
MS drug going to make hundreds of millions..

Dec 28 (Reuters) - TG Therapeutics Inc said on Wednesday that the U.S. health regulator had approved its monoclonal antibody for treating patients with relapsing forms of multiple sclerosis, sending its shares up nearly 9% in afternoon trade.

The approval by the U.S. Food and Drug Administration (FDA) widens the number of such drugs available for treating the disorder to three and may help soften the blow to the company's finances from the withdrawal of its lymphatic cancer drug earlier this year.

TG Therapeutics said it was expecting to launch the drug, branded as Brumvi, in the first quarter of 2023, but did not give details on its pricing.

Jefferies analyst Chris Howerton said ahead of the approval that he was expecting the drug to be priced in the range of $30,000 per patient per year. In comparison, Roche's Ocrevus has a current list price of about $68,000 annually.

Multiple sclerosis is a neurological disease in which the immune system attacks the brain cells causing motor disabilities. It affects about 400,000 people in the United States, according to the National Institutes of Health.

Unlike other MS drugs that target T cells, Brumvi belongs to a class of drugs that tackles B cells' role in driving the inflammation that is central to neurological disease.

The approval, which comes with a warning of infusion reactions from the drug, was based on a late-stage study that showed the drug was effective in reducing the annualized relapse rates in patients. (Reporting by Sriparna Roy, Khushi Mandowara and Raghav Mahobe in Bengaluru; Editing by Anil D'Silva and Shailesh Kuber)
👍️0
SpaceTimeRift777 SpaceTimeRift777 2 years ago
Nice Pump Moon Market
👍️0
tw0122 tw0122 2 years ago
As usual they going to scare folks into
Selling there shares loooks like upper $8s bottom
👍️0
tw0122 tw0122 2 years ago
Still holding about 20% regular short interest and then all the illegal naked Gary G approved ones
👍️0
makinezmoney makinezmoney 2 years ago
$TGTX: Opens at $11...........


Only the beginning now


GO $TGTX
👍️0
tw0122 tw0122 2 years ago
Can be whatever you want if we see $40s..lol
👍️0
Imarket13 Imarket13 2 years ago
God damn thought you were a woman this whole time
👍️0
makinezmoney makinezmoney 2 years ago
$TGTX: I showered.............

Balls, armpits and buttcrack............. good to go.

Took 2mins


GO $TGTX
👍️0
tw0122 tw0122 2 years ago
220pm stand corrected
alfred

@macronewswire
TG THERAPEUTICS (TGTX)TO RESUME TRADING AT 2:20 P.M.
$TGTX
👍️0
Imarket13 Imarket13 2 years ago
I'm hearing within the next hour... everyone wins!!
👍️0
makinezmoney makinezmoney 2 years ago
$TGTX: Fantastic !!!!!!!!!!!!!


Works for me



GO $TGTX
👍️0
tw0122 tw0122 2 years ago
Halted I believe until 830am
Press release tomorrow. Don’t take my word but pretty sure
👍️0
makinezmoney makinezmoney 2 years ago
$TGTX: Whats the big deal about PKPH ???

Did they just get an FDA approval like $TGTX ??

GO $TGTX
👍️0
makinezmoney makinezmoney 2 years ago
$TGTX: No comment


I hope it doesn't open till tomorrow............. then yer filthy for the next 23hrs



GO $TGTX
👍️0
halbroke1 halbroke1 2 years ago
makin..TGTX nice one, Im In !!.Check out pk*ph.., Real cheap
👍️0
Imarket13 Imarket13 2 years ago
Well they should be. Clean trading is key
👍️0

Your Recent History

Delayed Upgrade Clock